In the past week, RGNX stock has gone down by -0.45%, with a monthly gain of 3.63% and a quarterly plunge of -9.06%. The volatility ratio for the week is 8.68%, and the volatility levels for the last 30 days are 6.84% for Regenxbio Inc The simple moving average for the last 20 days is 12.69% for RGNX stock, with a simple moving average of -22.28% for the last 200 days.
Is It Worth Investing in Regenxbio Inc (NASDAQ: RGNX) Right Now?
RGNX has 36-month beta value of 1.26. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RGNX is 44.62M, and currently, short sellers hold a 11.00% ratio of that float. The average trading volume of RGNX on November 15, 2024 was 515.26K shares.
RGNX) stock’s latest price update
Regenxbio Inc (NASDAQ: RGNX) has seen a rise in its stock price by 4.40 in relation to its previous close of 10.67. However, the company has experienced a -0.45% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-11-14 that – Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenne ROCKVILLE, Md.
Analysts’ Opinion of RGNX
Many brokerage firms have already submitted their reports for RGNX stocks, with Raymond James repeating the rating for RGNX by listing it as a “Outperform.” The predicted price for RGNX in the upcoming period, according to Raymond James is $18 based on the research report published on October 10, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see RGNX reach a price target of $38. The rating they have provided for RGNX stocks is “Buy” according to the report published on June 07th, 2024.
H.C. Wainwright gave a rating of “Buy” to RGNX, setting the target price at $36 in the report published on March 11th of the current year.
RGNX Trading at 5.74% from the 50-Day Moving Average
After a stumble in the market that brought RGNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.32% of loss for the given period.
Volatility was left at 6.84%, however, over the last 30 days, the volatility rate increased by 8.68%, as shares surge +5.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.11% lower at present.
During the last 5 trading sessions, RGNX fell by -0.45%, which changed the moving average for the period of 200-days by -9.58% in comparison to the 20-day moving average, which settled at $9.89. In addition, Regenxbio Inc saw -37.94% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RGNX starting from KARABELAS ARGERIS N, who sale 10,000 shares at the price of $10.11 back on Oct 01 ’24. After this action, KARABELAS ARGERIS N now owns 11,286 shares of Regenxbio Inc, valued at $101,052 using the latest closing price.
KARABELAS ARGERIS N, the Director of Regenxbio Inc, sale 10,000 shares at $11.56 during a trade that took place back on Sep 03 ’24, which means that KARABELAS ARGERIS N is holding 11,286 shares at $115,588 based on the most recent closing price.
Stock Fundamentals for RGNX
Current profitability levels for the company are sitting at:
- -2.89 for the present operating margin
- 0.39 for the gross margin
The net margin for Regenxbio Inc stands at -2.83. The total capital return value is set at -0.59. Equity return is now at value -71.87, with -41.43 for asset returns.
Currently, EBITDA for the company is -239.46 million with net debt to EBITDA at -0.12. When we switch over and look at the enterprise to sales, we see a ratio of 6.87. The receivables turnover for the company is 3.35for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.05.
Conclusion
To put it simply, Regenxbio Inc (RGNX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
